Suppr超能文献

新型罗丹宁-噻唑杂化物作为潜在的抗糖尿病药物:基于结构的药物设计方法。

Novel rhodanine-thiazole hybrids as potential antidiabetic agents: a structure-based drug design approach.

作者信息

Gharge Shankar, Alegaon Shankar G, Ranade Shriram D, Kavalapure Rohini S, Kumar B R Prashantha

机构信息

Department of Pharmaceutical Chemistry, KLE College of Pharmacy, Belagavi, KLE Academy of Higher education and Research Belagavi - 590 010 Karnataka India

Department of Pharmaceutical Chemistry, JSS College of Pharmacy, Mysuru, JSS Academy of Higher Education and Research Mysuru-570015 Karnataka India.

出版信息

RSC Med Chem. 2024 Nov 21. doi: 10.1039/d4md00689e.

Abstract

New rhodanine-thiazole clubbed compounds (7a-7l) were synthesised and characterised with various spectroscopy methods. The synthesised hybrids underwent HPA, HLAG inhibition, and peroxisome proliferator-activated receptor-gamma (PPAR-γ) expression assays. Through the biological study, compound 7f showed promising inhibitory activity against HPA with an IC value of 27.13 ± 1.02 μM and 7l exhibited better inhibition against HLAG with an IC value of 24.21 ± 1.12 μM. In addition, Lineweaver-Burk plot analysis suggested that 7l and 7f behaved as a mixed type of HLAG and HPA inhibitor and further, compound 7f showed significant PPAR-γ expression as compared to controls in a dose dependent manner; the expression can be attributed to its mapped pharmacophoric features with a phase screen score of 1.28 and vector score of 0.62. The proteins modulated by compounds include , , and proteins , signalling pathways identified by cluster analysis and justified by molecular docking studies and MD trajectory analysis to evaluate the binding orientation and stability of the molecules, and the energy profiles of the molecules, both in complex with the protein, were assessed using MM/GBSA and DFT calculations, respectively. Finally, the pharmacokinetic profile was determined using ADMET analysis. Thus, from the above findings, it may demonstrate that rhodanine-thiazole hybrids constitute promising candidates in the pursuit of developing newer oral antidiabetic agents.

摘要

合成了新型罗丹宁 - 噻唑连接化合物(7a - 7l),并通过各种光谱方法对其进行了表征。对合成的杂化物进行了HPA、HLAG抑制和过氧化物酶体增殖物激活受体 - γ(PPAR - γ)表达测定。通过生物学研究,化合物7f对HPA表现出有前景的抑制活性,IC值为27.13±1.02μM,7l对HLAG表现出更好的抑制作用,IC值为24.21±1.12μM。此外,Lineweaver - Burk图分析表明,7l和7f表现为HLAG和HPA的混合型抑制剂,并且,与对照相比,化合物7f以剂量依赖性方式显示出显著的PPAR - γ表达;该表达可归因于其映射的药效团特征,相筛选评分为1.28,向量评分为0.62。化合物调节的蛋白质包括 、 和 蛋白质 ,通过聚类分析确定并经分子对接研究和MD轨迹分析证实的 信号通路,以评估分子的结合取向和稳定性,并且分别使用MM/GBSA和DFT计算评估了与蛋白质结合的分子的能量分布。最后,使用ADMET分析确定药代动力学特征。因此,从上述发现可以证明,罗丹宁 - 噻唑杂化物在开发新型口服抗糖尿病药物方面构成了有前景的候选物。

相似文献

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验